| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Terry J. Smith | Q45933677 |
| P2093 | author name string | Richard P Phipps | |
| Steven E Feldon | |||
| Geniece M Lehmann | |||
| P2860 | cites work | Why there are two cyclooxygenase isozymes | Q27863307 |
| A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells | Q28187669 | ||
| Graves' ophthalmopathy: a preventable disease? | Q28210494 | ||
| Peroxisome proliferator-activated receptor gamma in diabetes and metabolism | Q28263756 | ||
| The PPARs: from orphan receptors to drug discovery | Q28371618 | ||
| 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma | Q29615221 | ||
| A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation | Q29619212 | ||
| PPAR gamma is required for placental, cardiac, and adipose tissue development | Q29619912 | ||
| Peroxisome proliferator-activated receptor γ in diabetes and metabolism | Q30040168 | ||
| Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation | Q34434772 | ||
| The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus | Q34525244 | ||
| Prostaglandins as modulators of immunity | Q34543566 | ||
| The pathophysiology of thyroid-associated ophthalmopathy | Q34684417 | ||
| Emerging roles of PPARs in inflammation and immunity | Q34931884 | ||
| Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes | Q35222158 | ||
| The relation of Graves' ophthalmopathy to circulating thyroid hormone status | Q35591694 | ||
| The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. | Q35605719 | ||
| Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. | Q35606170 | ||
| Circulating fibrocytes: collagen-secreting cells of the peripheral blood | Q35686362 | ||
| Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts | Q72055491 | ||
| Pathogenesis of Graves' ophthalmopathy--current understanding | Q73397377 | ||
| The roles of CD28 and CD40 ligand in T cell activation and tolerance | Q73709036 | ||
| The risk of diplopia following orbital floor and medial wall decompression in subtypes of ophthalmic Graves' disease | Q73719202 | ||
| Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy | Q74324679 | ||
| Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves' ophthalmopathy and other thyroid and nonthyroid diseases | Q74336320 | ||
| Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophth | Q77478013 | ||
| Cyclooxygenase-1 and -2 are expressed by human T cells | Q77953372 | ||
| Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study | Q79546631 | ||
| Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion | Q80061323 | ||
| Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression | Q82927501 | ||
| Thy-1 Expression in Human Fibroblast Subsets Defines Myofibroblastic or Lipofibroblastic Phenotypes | Q35792099 | ||
| Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation | Q35834935 | ||
| Peroxisome proliferator-activated receptor ligands in atherosclerosis | Q35925566 | ||
| Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis | Q35971144 | ||
| The clinical potential of chemokine receptor antagonists | Q36127913 | ||
| Insights into the role of fibroblasts in human autoimmune diseases. | Q36208013 | ||
| Antigen processing by autoreactive B cells promotes determinant spreading | Q36280504 | ||
| The induction and maintenance of T cell anergy | Q36438018 | ||
| The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. | Q36462675 | ||
| The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond | Q36493978 | ||
| Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. | Q36494390 | ||
| Anergic B cells caught in the act. | Q36686623 | ||
| Role of abatacept in the management of rheumatoid arthritis | Q36703204 | ||
| Development in motion: helper T cells at work | Q36785612 | ||
| Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies | Q36970632 | ||
| Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy | Q37515485 | ||
| A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity | Q38361522 | ||
| Graves' ophthalmopathy: current concepts regarding pathogenesis and management | Q39489563 | ||
| The myofibroblast: a key cell for wound healing and fibrocontractive diseases | Q40306275 | ||
| Helper T cells: delivery of cell contact and lymphokine-dependent signals to B cells. | Q40386987 | ||
| CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism | Q40445070 | ||
| Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis | Q40625104 | ||
| 15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes | Q40757735 | ||
| Orbital tissue-derived T lymphocytes from patients with Graves' ophthalmopathy recognize autologous orbital antigens | Q41180349 | ||
| CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. | Q41332088 | ||
| Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy | Q41671098 | ||
| Differential activation of peroxisome proliferator-activated receptors by eicosanoids. | Q42276729 | ||
| Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism | Q42485253 | ||
| Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts | Q43845891 | ||
| Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy | Q43853007 | ||
| Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes | Q43867818 | ||
| Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. | Q45096631 | ||
| Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway | Q46107628 | ||
| Human lupus T cells resist inactivation and escape death by upregulating COX-2. | Q48022316 | ||
| Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. | Q52117482 | ||
| Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. | Q52529880 | ||
| Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. | Q53437653 | ||
| Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. | Q53611171 | ||
| Ligation of CD28 in vivo induces CD40 ligand expression and promotes B cell survival | Q56906640 | ||
| Pathogenesis of Graves' ophthalmopathy | Q70513409 | ||
| Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy | Q70587767 | ||
| Clinical significance of extraocular muscle volumes in Graves' ophthalmopathy: a quantitative computed tomography study | Q71860926 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 959-965 | |
| P577 | publication date | 2008-09-01 | |
| P1433 | published in | Thyroid | Q15709940 |
| P1476 | title | Immune mechanisms in thyroid eye disease | |
| P478 | volume | 18 |
| Q58728096 | Biomarker identification of thyroid associated ophthalmopathy using microarray data |
| Q36133982 | CD40 Expression in Fibrocytes Is Induced by TSH: Potential Synergistic Immune Activation |
| Q54177827 | CD40 ligand induces expression of vascular cell adhesion molecule 1 and E-selectin in orbital fibroblasts from patients with Graves' orbitopathy. |
| Q53362208 | Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy. |
| Q35971151 | Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy. |
| Q37422118 | Fat circadian biology |
| Q99371195 | Identification of differentially expressed long non-coding RNAs and mRNAs in orbital adipose/connective tissue of thyroid-associated ophthalmopathy |
| Q52871558 | Immunoglobulin G4-positive staining of orbital lesions in thyroid eye disease: Report of two cases. |
| Q36478242 | Inhibitory Effects of α-Lipoic Acid on Oxidative Stress-Induced Adipogenesis in Orbital Fibroblasts From Patients With Graves Ophthalmopathy |
| Q90894014 | Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy |
| Q40601963 | Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease |
| Q35738996 | Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-β Induced Myofibroblast Differentiation via Prostaglandin E2 |
| Q34149741 | Novel anti-adipogenic activity produced by human fibroblasts. |
| Q39159003 | Orbital Decompression for Thyroid Eye Disease |
| Q37296579 | Orbital fibroblasts from thyroid eye disease patients differ in proliferative and adipogenic responses depending on disease subtype |
| Q24201984 | Orbital radiotherapy for adult thyroid eye disease |
| Q38633022 | Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. |
| Q34998187 | Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts |
| Q34062319 | Quercetin inhibits IL-1β-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves' orbitopathy |
| Q38948145 | Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy |
| Q37114625 | Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation |
| Q35055573 | Salinomycin and other polyether ionophores are a new class of antiscarring agent |
| Q37576094 | Selected lid problems in neurologic practice |
| Q38292241 | Selenium: an element for life |
| Q38795531 | The Aryl Hydrocarbon Receptor and Its Ligands Inhibit Myofibroblast Formation and Activation: Implications for Thyroid Eye Disease |
| Q37784810 | The Orbital Fibroblast: A Key Player and Target for Therapy in Graves’ Ophthalmopathy |
| Q34805707 | The aryl hydrocarbon receptor ligand ITE inhibits TGFβ1-induced human myofibroblast differentiation |
| Q95322318 | The aryl hydrocarbon receptor pathway controls matrix metalloproteinase-1 and collagen levels in human orbital fibroblasts |
| Q64993448 | The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. |
| Q35576492 | Thy1 (CD90) controls adipogenesis by regulating activity of the Src family kinase, Fyn |
| Q37060528 | Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management. |
| Q93333216 | Tocilizumab for thyroid eye disease |
| Q94355143 | Tocilizumab for thyroid eye disease |
| Q60049891 | Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy |
Search more.